430 Dose finding of inecalcitol, a new VDR agonist, in combination with docetaxel–prednisone regimen for castrate-resistant prostate cancer (HRPC) patients (pts)

Autor:	J. Medioni, T. Maurina, J.M. Rodier, S. Renaux, J-M Ferrero, G. Deplanque, G. Allyon, Eric Raymond, Stéphane Oudard, J.F. Dufour-Lamartinie
Rok vydání:	2010
Předmět:	Oncology Agonist Cancer Research medicine.medical_specialty business.industry medicine.drug_class Castrate-resistant prostate cancer Calcitriol receptor Inecalcitol Dose finding Internal medicine Medicine Docetaxel-Prednisone Regimen business
Zdroj:	European Journal of Cancer Supplements. 8:136
ISSN:	1359-6349
DOI:	10.1016/s1359-6349(10)72137-6
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::807c3f83c0fe8bfabf91a2a0fb87b7b2 https://doi.org/10.1016/s1359-6349(10)72137-6 Zobrazit plný text záznamu Full Text from ScienceDirect